REGN5678

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Prostate CancerMetastatic Castration-Resistant Prostate Cancer, Mcrpc

314 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

1

Lupron

EEastern Cooperative Oncology Group

Phase 3

532

Nizoral

WWim Janssens

Phase 3

213

Acetylsalicylic Acid

Bayer

Phase 3

24

Androgen Deprivation Treatment

MMedical University of Vienna

Phase 3

15

Lupron Depot

RRepros Therapeutics Inc.

Phase 3

26

Trexall

Jazz Pharmaceuticals

Preclinical

—7

REGN5678

Regeneron

Phase 2

38

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

29

Duragesic

CCephalon

Preclinical

110

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1Show 20 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Prostate Cancer3 trials

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer

Recruiting·Regeneron·Phase 1/2·NCT05125016·370 enrolled

A Pilot Presurgical Trial of REGN5678 (Anti-PSMA X CD28) in Patients With High-Risk, Localized Prostate Cancer Followed by Radical Prostatectomy

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT06085664·42 enrolled

A Phase Ib Clinical Trial to Optimize Risk Benefit of REGN5678 (PSMAxCD28 Bispecific Antibody) Plus Cemiplimab (Anti-PD-1 Monoclonal Antibody) in Patients With Metastatic Castration-resistant Prostate Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06826768·60 enrolled

Metastatic Castration-resistant Prostate Cancer, mCRPC1 trial

A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression

Recruiting·Regeneron·Preclinical·NCT03972657·345 enrolled

Details

Drug Info

Related News